0000950170-23-010439.txt : 20230329 0000950170-23-010439.hdr.sgml : 20230329 20230329080858 ACCESSION NUMBER: 0000950170-23-010439 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230328 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230329 DATE AS OF CHANGE: 20230329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 23771825 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 8-K 1 crsp-20230328.htm 8-K 8-K
00-00000000001674416false00016744162023-03-282023-03-28

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 28, 2023

 

 

CRISPR THERAPEUTICS AG

(Exact name of Registrant as Specified in Its Charter)

 

 

Switzerland

001-37923

Not Applicable

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Baarerstrasse 14

 

6300 Zug, Switzerland

 

Not Applicable

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 41 (0)41 561 32 77

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, nominal value CHF 0.03

 

CRSP

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 28, 2023, Bradley Bolzon, Ph.D. notified the Board of Directors of CRISPR Therapeutics AG (the “Company”) of his intention to resign as a director of the Company, effective as of the close of business on March 28, 2023. Dr. Bolzon’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.

The full text of the press release announcing Dr. Bolzon’s resignation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit
No.

 

 

Description

 

 

99.1

 

Press Release by CRISPR Therapeutics AG, dated March 29, 2023

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CRISPR Therapeutics AG

 

 

 

 

Date:

 March 29, 2023

By:

/s/ Samarth Kulkarni

 

 

 

Samarth Kulkarni, Ph.D.
Chief Executive Officer

 

 

 

 EX-99 2 crsp-ex99_1.htm EX-99.1 EX-99

Exhibit 99.1

CRISPR Therapeutics Announces Departure of Board Member

 

ZUG, Switzerland and Boston, Mass., March 29, 2023 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

 

“From the very beginning, Brad has been instrumental in defining the vision and strategy for CRISPR Therapeutics and has guided the company through many stages of development,” said Rodger Novak, M.D., President and Chairman of the Board of CRISPR Therapeutics. “It has been a pleasure working with him and I would personally like to thank Brad for his ongoing support.”

 

“Brad has made immeasurable contributions to the company since its founding and has been a driving force behind the company’s success,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “His extensive experience and strategic insights have been critical in establishing CRISPR Therapeutics as a pre-eminent gene editing company, and more importantly, in bringing life-saving medicines to patients. I am personally grateful for his counsel, and on behalf of our Board of Directors and the management team, I would like to thank him for his years of service on the Board.”

 

“I am very proud of this leadership team’s many accomplishments over the past decade,” said Dr. Bolzon. “CRISPR Therapeutics exemplifies what life science venture capitalists strive for -- generating significant value for all shareholders and, most importantly, pioneering the next generation of medicines to help those patients most in need. I wish management and the board further success on this journey and have the utmost confidence that they will continue to execute at the highest level.”

 

About CRISPR Therapeutics

 

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

 

CRISPR THERAPEUTICS® word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

 

Investor Contact:

Susan Kim

+1-617-315-4600

susan.kim@crisprtx.com

 

Media Contact:

Rachel Eides

 

+1-617-315-4493

rachel.eides@crisprtx.com

 EX-101.SCH 3 crsp-20230328.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.PRE 4 crsp-20230328_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 5 crsp-20230328_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Soliciting Material Amendment Flag Entity Incorporation, State or Country Code City Area Code Document Period End Date Entity Address, Postal Zip Code Entity File Number Entity Address, Address Line One Entity Tax Identification Number Entity Emerging Growth Company Entity Registrant Name Pre Commencement Tender Offer Security 12b Title Document Type Written Communications Security Exchange Name Entity Address, Country Entity Central Index Key Local Phone Number Pre Commencement Issuer Tender Offer Cover [Abstract] Trading Symbol XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Mar. 28, 2023
Cover [Abstract]  
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001674416
Document Type 8-K
Document Period End Date Mar. 28, 2023
Entity Registrant Name CRISPR THERAPEUTICS AG
Entity Incorporation, State or Country Code V8
Entity File Number 001-37923
Entity Address, Address Line One Baarerstrasse 14
Entity Address, Postal Zip Code 6300
Entity Address, City or Town Zug
Entity Address, Country CH
City Area Code 41 (0)41
Local Phone Number 561 32 77
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Shares, nominal value CHF 0.03
Trading Symbol CRSP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 crsp-20230328_htm.xml IDEA: XBRL DOCUMENT 0001674416 2023-03-28 2023-03-28 00-0000000 0001674416 false 8-K 2023-03-28 CRISPR THERAPEUTICS AG V8 001-37923 Baarerstrasse 14 6300 Zug CH 41 (0)41 561 32 77 false false false false Common Shares, nominal value CHF 0.03 CRSP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports crsp-20230328.htm crsp-20230328.xsd crsp-20230328_lab.xml crsp-20230328_pre.xml crsp-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "crsp-20230328.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "crsp-20230328.htm" ] }, "labelLink": { "local": [ "crsp-20230328_lab.xml" ] }, "presentationLink": { "local": [ "crsp-20230328_pre.xml" ] }, "schema": { "local": [ "crsp-20230328.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crsp", "nsuri": "http://www.crisprtx.com/20230328", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230328.htm", "contextRef": "C_d94375ea-0fb2-4944-95a7-9742c8e85450", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230328.htm", "contextRef": "C_d94375ea-0fb2-4944-95a7-9742c8e85450", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230328/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-010439-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-010439-xbrl.zip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